Open Nav


  • Pedro Lichtinger, ChemioCare

Pre-IPO exposure to investors

  • Date:Wednesday, October 17
  • Time:10:30 AM - 10:45 AM
  • Room:Elizabethan A
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:Transforming the treatment of chemotherapy induced nausea and vomiting (CINV) through transdermal patch technology.
  • Company
  • Company HQ City:New York
  • Company HQ Country:United States
  • Company HQ State:New York                    
  • CEO/Top Company Official:Pedro Lichtinger
  • Year Founded:2017
  • Main Therapeutic Focus:Oncology
  • Lead Product in Development :Ondansetron 5-day transdermal patch
  • Development Phase of Primary Product:Pre-Clinical
  • Number Of Unlicensed Products (For Which You Are Seeking Partners) :4
  • Additional Information/Comments:Nasdaq/TSX IPO planned for 1H-2019.
  • Size of Last Investment Round:4.5
  • Total Amount Raised to Date, In All Rounds:$6.8M
Pedro Lichtinger